Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada.
Niraparib was recently funded in Canada for the maintenance treatment of ovarian cancer following platinum-based chemotherapy. However, the drug's safety profile in the real world remains uncertain. We conducted a cohort study to describe the patient population using niraparib and the proportion tha...
| Publicado en: | Current Oncology Vol. 31; no. 6; pp. 3591 - 3603 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jun2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=178152609&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 178152609 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Jun2024 vid: 31 iid: 6 pid: 97109 pub: MDPI artinfo: ui: 178152609 10.3390/curroncol31060264 178152609 ppf: 3591 ppct: 12 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada. aug: au: Guan, Qi Aktar, Suriya J. Pataky, Reka E. Stephen, Mariet Mathew Marques, Maud Gambaro, Karen Rachedi, Kahina Forster, Katharina Strub, Samara Stock, David de Léséleuc, Louis Cheung, Winson Y. Peacock, Stuart Farrer, Christie Gavura, Scott Tadrous, Mina Grant, Robert C. Chan, Kelvin K. W. affil: Ontario Health, Toronto, ON M5G 2L3, Canada sug: ab: Niraparib was recently funded in Canada for the maintenance treatment of ovarian cancer following platinum-based chemotherapy. However, the drug's safety profile in the real world remains uncertain. We conducted a cohort study to describe the patient population using niraparib and the proportion that experienced adverse events between June 2019 and December 2022 in four Canadian provinces (Ontario, Alberta, British Columbia [BC], and Quebec). We used administrative data and electronic medical records from Ontario Health, Alberta Health Services, and BC Cancer, and registry data from Exactis Innovation. We summarized baseline characteristics using descriptive statistics and reported safety outcomes using cumulative incidence. We identified 514 patients receiving niraparib. Mean age was 67 years and most were initiated on a daily dose of 100 or 200 mg/day. Grade 3/4 anemia, neutropenia, and thrombocytopenia occurred in 11–16% of the cohort. In Ontario, the three-month cumulative incidence of grade 3/4 thrombocytopenia was 11.6% (95% CI, 8.3–15.4%), neutropenia was 7.1% (95% CI, 4.6–10.4%), and anemia was 11.3% (95% CI, 8.0–15.2%). Cumulative incidences in the remaining provinces were similar. Initial daily dose and proportions of hematological adverse events were low in the real world and may be related to cautious prescribing and close monitoring by clinicians. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|